Diamyd Medical AB (publ)

DB:DMN Stock Report

Market Cap: €117.2m

Diamyd Medical Management

Management criteria checks 3/4

Diamyd Medical's CEO is Ulf Hannelius, appointed in Apr 2016, has a tenure of 8.58 years. total yearly compensation is SEK3.01M, comprised of 70.9% salary and 29.1% bonuses, including company stock and options. directly owns 0.27% of the company’s shares, worth €318.63K. The average tenure of the management team and the board of directors is 4.8 years and 20.8 years respectively.

Key information

Ulf Hannelius

Chief executive officer

SEK 3.0m

Total compensation

CEO salary percentage70.9%
CEO tenure8.6yrs
CEO ownership0.3%
Management average tenure4.8yrs
Board average tenure20.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ulf Hannelius's remuneration changed compared to Diamyd Medical's earnings?
DateTotal CompensationSalaryCompany Earnings
Aug 31 2024n/an/a

-SEK 152m

May 31 2024n/an/a

-SEK 140m

Feb 29 2024n/an/a

-SEK 120m

Nov 30 2023n/an/a

-SEK 116m

Aug 31 2023SEK 3mSEK 2m

-SEK 116m

May 31 2023n/an/a

-SEK 119m

Feb 28 2023n/an/a

-SEK 115m

Nov 30 2022n/an/a

-SEK 99m

Aug 31 2022SEK 3mSEK 2m

-SEK 104m

May 31 2022n/an/a

-SEK 91m

Feb 28 2022n/an/a

-SEK 106m

Nov 30 2021n/an/a

-SEK 83m

Aug 31 2021SEK 3mSEK 2m

SEK 60m

May 31 2021n/an/a

SEK 74m

Feb 28 2021n/an/a

SEK 99m

Nov 30 2020n/an/a

SEK 121m

Aug 31 2020SEK 3mSEK 2m

SEK 10m

May 31 2020n/an/a

SEK 13m

Feb 29 2020n/an/a

SEK 13m

Nov 30 2019n/an/a

-SEK 35m

Aug 31 2019SEK 2mSEK 1m

-SEK 37m

May 31 2019n/an/a

-SEK 38m

Feb 28 2019n/an/a

-SEK 43m

Nov 30 2018n/an/a

-SEK 42m

Aug 31 2018SEK 2mSEK 1m

-SEK 44m

Compensation vs Market: Ulf's total compensation ($USD275.24K) is below average for companies of similar size in the German market ($USD476.59K).

Compensation vs Earnings: Ulf's compensation has increased whilst the company is unprofitable.

CEO

Ulf Hannelius (49 yo)

8.6yrs

Tenure

SEK 3,006,000

Compensation

Mr. Ulf Hannelius, PhD, MBA, has been the Chief Executive Officer of Diamyd Medical AB (publ) since April 11, 2016 and serves as its President. Mr. Hannelius served as an Interim Chief Executive Officer at...

Leadership Team

NamePositionTenureCompensationOwnership
Ulf Hannelius
CEO & President8.6yrsSEK 3.01m0.27%
€ 318.6k
Anna Styrud
Chief Financial Officerno datano data0.14%
€ 160.5k
Martina Widman
Chief Operating Officer2.4yrsno data0.012%
€ 14.1k
Anton Lindqvist
Chief Scientific Officer7.2yrsno datano data
Maja Johansson
Chief Operating Officer of Manufacturing Site1.8yrsno data0.0024%
€ 2.8k

4.8yrs

Average Tenure

49yo

Average Age

Experienced Management: DMN's management team is considered experienced (4.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ake Lernmark
Member of the Scientific Advisory Board28.8yrsno datano data
David Leslie
Member of the Scientific Advisory Board25.8yrsno datano data
Daniel Kaufman
Member of the Scientific Advisory Board28.8yrsno datano data
Anders Essen-Möller
Independent Chairman28.8yrsSEK 1.06m3.13%
€ 3.7m
Mark Atkinson
Chairman of Scientific Advisory Board & Independent Director27.8yrsSEK 175.00k0.016%
€ 18.9k
Karin Hehenberger
Independent Director3.6yrsSEK 125.00k0.0096%
€ 11.3k
Erik Nerpin
Independent Vice Chairman12.8yrsSEK 230.00k0.056%
€ 66.1k
Torbjörn Bäckström
Independent Director7.8yrsSEK 138.00k0.00096%
€ 1.1k
Maria-Teresa Essen-Möller
Independent Director15.8yrsSEK 164.00k1.31%
€ 1.5m
Karin Rosen
Independent Director1.7yrsSEK 28.00k0.000010%
€ 11.7

20.8yrs

Average Tenure

65.5yo

Average Age

Experienced Board: DMN's board of directors are seasoned and experienced ( 20.8 years average tenure).